Haotian Guo

Haotian Guo, Jing Han, Yongfeng Tu et al.

Despite extensive research on textual and visual disambiguation, disambiguation through speech (DTS) remains underexplored. This is largely due to the lack of high-quality datasets that pair spoken sentences with richly ambiguous text. To address this gap, we present DEBATE, a unique public Chinese speech-text dataset designed to study how speech cues and patterns-pronunciation, pause, stress and intonation-can help resolve textual ambiguity and reveal a speaker's true intent. DEBATE contains 1,001 carefully selected ambiguous utterances, each recorded by 10 native speakers, capturing diverse linguistic ambiguities and their disambiguation through speech. We detail the data collection pipeline and provide rigorous quality analysis. Additionally, we benchmark three state-of-the-art large speech and audio-language models, illustrating clear and huge performance gaps between machine and human understanding of spoken intent. DEBATE represents the first effort of its kind and offers a foundation for building similar DTS datasets across languages and cultures. The dataset and associated code are available at: https://github.com/SmileHnu/DEBATE.

Haotian Guo, Hui Liu

The generation of high-quality candidate molecules remains a central challenge in AI-driven drug design. Current phenotype-based and target-based strategies each suffer limitations, either incurring high experimental costs or overlook system-level cellular responses. To bridge this gap, we propose ExMoIRL, a novel generative framework that synergistically integrates phenotypic and target-specific cues for de novo molecular generation. The phenotype-guided generator is first pretrained on expansive drug-induced transcriptional profiles and subsequently fine-tuned via multi-objective reinforcement learning (RL). Crucially, the reward function fuses docking affinity and drug-likeness scores, augmented with ranking loss, prior-likelihood regularization, and entropy maximization. The multi-objective RL steers the model toward chemotypes that are simultaneously potent, diverse, and aligned with the specified phenotypic effects. Extensive experiments demonstrate ExMoIRL's superior performance over state-of-the-art phenotype-based and target-based models across multiple well-characterized targets. Our generated molecules exhibit favorable drug-like properties, high target affinity, and inhibitory potency (IC50) against cancer cells. This unified framework showcases the synergistic potential of combining phenotype-guided and target-aware strategies, offering a more effective solution for de novo drug discovery.